Free Trial

Exact Sciences (EXAS) Stock Price, News & Analysis

$69.21
+1.22 (+1.79%)
(As of 04:37 PM ET)

About Exact Sciences Stock (NASDAQ:EXAS)

Key Stats

Today's Range
$67.01
$70.82
50-Day Range
$44.84
$69.48
52-Week Range
$40.62
$79.62
Volume
1.58 million shs
Average Volume
2.67 million shs
Market Capitalization
$12.77 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$78.14
Consensus Rating
Buy

Company Overview

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Exact Sciences Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks

Overall MarketRank™: 82nd Percentile

Exact Sciences scored higher than 82% of companies evaluated by MarketBeat, and ranked 220th out of 1,014 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Exact Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 15 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Exact Sciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Exact Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Exact Sciences are expected to grow in the coming year, from ($0.87) to ($0.06) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Exact Sciences is -51.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Exact Sciences is -51.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Exact Sciences has a P/B Ratio of 3.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Exact Sciences' valuation and earnings.
  • Percentage of Shares Shorted

    7.86% of the outstanding shares of Exact Sciences have been sold short.
  • Short Interest Ratio / Days to Cover

    Exact Sciences has a short interest ratio ("days to cover") of 5.3.
  • Change versus previous month

    Short interest in Exact Sciences has recently increased by 4.99%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Exact Sciences does not currently pay a dividend.

  • Dividend Growth

    Exact Sciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.86% of the outstanding shares of Exact Sciences have been sold short.
  • Short Interest Ratio / Days to Cover

    Exact Sciences has a short interest ratio ("days to cover") of 5.3.
  • Change versus previous month

    Short interest in Exact Sciences has recently increased by 4.99%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Exact Sciences has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 27 news articles for Exact Sciences this week, compared to 8 articles on an average week.
  • Search Interest

    Only 6 people have searched for EXAS on MarketBeat in the last 30 days. This is a decrease of -77% compared to the previous 30 days.
  • MarketBeat Follows

    10 people have added Exact Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Exact Sciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.36% of the stock of Exact Sciences is held by insiders.

  • Percentage Held by Institutions

    88.82% of the stock of Exact Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Exact Sciences' insider trading history.
Receive EXAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.

EXAS Stock News Headlines

China Stockpiling Gold “Like No Tomorrow”
For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… .
Buy Rating Affirmed for Exact Sciences Following Promising CRC Screening Test Data
Exact Sciences Sees Unusually High Options Volume (NASDAQ:EXAS)
Exact Sciences Unusual Options Activity For September 16
Piper Sandler Boosts Exact Sciences (NASDAQ:EXAS) Price Target to $85.00
See More Headlines

EXAS Stock Analysis - Frequently Asked Questions

Exact Sciences' stock was trading at $73.98 at the beginning of the year. Since then, EXAS stock has decreased by 7.3% and is now trading at $68.58.
View the best growth stocks for 2024 here
.

Exact Sciences Co. (NASDAQ:EXAS) issued its earnings results on Wednesday, July, 31st. The medical research company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.28. The business's revenue for the quarter was up 12.4% compared to the same quarter last year.

Exact Sciences subsidiaries include Ashion Analytics, Thrive Earlier Detection Corporation, Base Genomics Limited, Paradigm Diagnostics Inc., Viomics Inc., Biomatrica Inc., Armune BioScience, and more.

Top institutional shareholders of Exact Sciences include William Blair Investment Management LLC (2.10%), Ensign Peak Advisors Inc (0.98%), Baillie Gifford & Co. (0.77%) and Armistice Capital LLC (0.76%). Insiders that own company stock include Kevin T Conroy, Sarah Condella, Katherine S Zanotti, James Edward Doyle, Everett Cunningham, D Scott Coward, Daniel J Levangie, Jacob A Orville, Brian Baranick, Jeffrey Thomas Elliott and James Herriott.
View institutional ownership trends
.

Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL) and Block (SQ).

Company Calendar

Last Earnings
7/31/2024
Today
9/18/2024
Next Earnings (Estimated)
11/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:EXAS
CUSIP
30063P10
Employees
6,600
Year Founded
1995

Price Target and Rating

Average Stock Price Target
$78.14
High Stock Price Target
$95.00
Low Stock Price Target
$67.00
Potential Upside/Downside
+16.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
15 Analysts

Profitability

Net Income
$-204,150,000.00
Pretax Margin
-6.59%

Debt

Sales & Book Value

Annual Sales
$2.61 billion
Cash Flow
$0.02 per share
Book Value
$17.39 per share

Miscellaneous

Free Float
182,020,000
Market Cap
$12.42 billion
Optionable
Optionable
Beta
1.26

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:EXAS) was last updated on 9/18/2024 by MarketBeat.com Staff
From Our Partners